Linked Life Data

16432832

Source:http://linkedlifedata.com/resource/pubmed/id/16432832

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2006-4-24
pubmed:abstractText
Serological screening approaches have allowed for the identification of a large number of potentially relevant tumor antigens in cancer patients. Within this group, cancer testis antigens represent promising targets for cancer immunotherapy, since they are widely expressed in a variety of human cancer entities. In pancreatic cancer, however, there are only few data available about the expression pattern and serological response to cancer testis antigens and other serological-defined tumor antigens. Therefore, we investigated the IgG antibody response against 11 cancer testis antigens (SCP-1, GAGE, LAGE-1a,-1b, CT-7, NY-ESO-1, SSX-1-5) recombinantly expressed on yeast surface (RAYS) in patients with pancreatic cancer (n = 96), chronic pancreatitis (n = 18) and healthy donors (n = 48). We found in 14% of all patients antibody responses to SCP-1, but not to other cancer testis antigens (GAGE, LAGE-1a,-1b, CT-7, NY-ESO-1, SSX-1-5). Antibody response correlated with the expression of SCP-1 in the primary tumor of the respective patient as shown by RT-PCR, immunohistochemistry and Western blot. In contrast, no serological response to cancer testis antigens was observed in healthy donors. The humoral immune response against SCP-1 was associated with the size of tumor, but not with other clinico-pathological parameters such as histology, stage, presence of lymph node metastases, grading, age, gender or gemcitabine treatment. In conclusion, antibody response to cancer testis antigen SCP-1 is found in a proportion of pancreatic carcinoma patients. These results indicate that identification of additional tumor antigens by serological screening of tumor cDNA expression libraries by RAYS is a promising goal in pancreatic cancer.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0020-7136
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
119
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
117-25
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:16432832-Aged, pubmed-meshheading:16432832-Antigens, Neoplasm, pubmed-meshheading:16432832-Blotting, Western, pubmed-meshheading:16432832-Cell Line, Tumor, pubmed-meshheading:16432832-Female, pubmed-meshheading:16432832-Flow Cytometry, pubmed-meshheading:16432832-Fluorescent Antibody Technique, pubmed-meshheading:16432832-Gene Expression Regulation, Neoplastic, pubmed-meshheading:16432832-Humans, pubmed-meshheading:16432832-Immunohistochemistry, pubmed-meshheading:16432832-Male, pubmed-meshheading:16432832-Membrane Proteins, pubmed-meshheading:16432832-Middle Aged, pubmed-meshheading:16432832-Nuclear Proteins, pubmed-meshheading:16432832-Pancreatic Neoplasms, pubmed-meshheading:16432832-Phosphoprotein Phosphatases, pubmed-meshheading:16432832-Reverse Transcriptase Polymerase Chain Reaction, pubmed-meshheading:16432832-Testis, pubmed-meshheading:16432832-Tumor Markers, Biological
pubmed:year
2006
pubmed:articleTitle
Serological immune response to cancer testis antigens in patients with pancreatic cancer.
pubmed:affiliation
Department of Internal Medicine I, University of Saarland Medical School, Homburg/Saar, Germany.
pubmed:publicationType
Journal Article, Comparative Study, Research Support, Non-U.S. Gov't